# LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

> **NCT04973527** · PHASE1 · TERMINATED · sponsor: **Beijing Boren Hospital** · enrollment: 9 (actual)

## Conditions studied

- T Cell Lymphoma
- T-cell Leukemia

## Interventions

- **DRUG:** Efficacy of LCAR-T2C CAR-T cells

## Key facts

- **NCT ID:** NCT04973527
- **Lead sponsor:** Beijing Boren Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-02
- **Primary completion:** 2022-07-11
- **Final completion:** 2022-07-20
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Both the sponsors and collaborator are considering terminating the study
- **Last updated:** 2022-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04973527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04973527, "LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT04973527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*